| Issue |
Korean Chemical Engineering Research,
Vol.46, No.2, 211-216, 2008
Vol.46, No.2, 211-216, 2008
마이크로니들시스템을 이용한 부펙사막의 경피전달
Transdermal Delivery of Bufexamac using Microneedle System
아토피의 치료를 위해 사용되는 부펙사막은 연고제 형태로 사용되는 약물이다. 부펙사막은 피부 장벽효과에 의해 실제 전달되는 양은 매우 적다. 이러한 문제를 갖는 부펙사막의 피부전달 효율을 증가시키기 위하여 마이크로니들을 이용해 피부처리를 실시하였다. 약물의 피부투과량과 피부에서 약물의 전달형태를 알아보기 위하여 부펙사막에 FITC를 결합시켰으며 이를 포함하는 하이드로겔을 제조하여 피부에 도포하였다. 약물의 피부투과량을 확인하기 위해서 형광분광계를 사용하여 분석하였으며 약물의 전달형태를 확인하기 위하여 형광필터가 장착된 마이크로현미경을 사용하였다. 실험결과 마이크로니들로 처리된 피부에서 부펙사막의 피부투과량이 대조군에 비해 5~20배 이상 증가되었으며 마이크로니들 처리횟수가 증가함에 따라서 더 크게 증가될 수 있음을 확인하였다.
Bufexamac which was used for treatment of atopic dermatitis is the drug which was made as the ointment. However, penetration rate of bufexamac was very low for the barrier effect of stratum corneum. Microneedle was used to increase transdermal delivery rate of the bufexamac. We tried to conjugate bufexamac and FITC for the detection of penetration rate of bufexamac. FITC-bufexamac was mixed in hydrogel for the treatment skin surface. Fluorescent spectrophotometer was used to analysis the concentration of FITC-bufexamac. Microscope using fluorescent filter was used to capture the image about location of FITC-bufexamac in the skin. We confirmed that permeation rate of bufexamac was increased with the treatment by microneedle and was increased by the increasing number treatment of microneedle.
[References]
- Mihara K, Kuratani K, Matsuim T, Nakamura M, Yokota K, Br. J. Dermatol., 151, 335, 2004
- Homey B, Steinhoff M, Ruzicka T, Leung DY, J. Allergy Clin. Immunol., 118, 178, 2006
- Lee HB, Khang G, Lee JH, CRC Biomedical Engineering Handbook, 2nd Edition, 39, 581, 2000
- Lee HB, Khang G, Cho JC, ACS Symp., 752, 385, 2000
- Lee CR, Kim MS, Khang G, Lee HK, Rhee JM, Lee HB, Tissue Eng. Regen. Med., 3(2), 85, 2006
- Khang G, Seong H, Lee HB, Edited by G-H. Hsuie, T. Okano, Y.U. Kim, H-W Sung, N. Yui and K. D. Park, Princeton Inter. Pub. Co. Ltd., Taipei, Taiwan, 537-558, 2002
- Ko JT, Jung HJ, Mo JH, Cho JS, Yuk SH, Shin HS, Kim MS, Rhee JM, Lee HB, Khang G, Key Eng. Mater., 342, 513, 2007
- Khang G, Choi HS, Rhee JM, Yoon SC, Cho JC, Lee HB, Korea Polym. J., 8(6), 253, 2000
- Seo SA, Choi HS, Lee DH, Khang G, Lee HB, Polym.(Korea), 25(6), 884, 2001
- Lee JS, An TK, Shin PK, Chae GS, Jeong JK, Lee B, Cho SH, Khang G, Lee HB, Polym.(Korea), 27(3), 217, 2003
- Khang G, Ku J, Lee B, Lee HB, Biomater. Res., 4(1), 20, 2000
- Hebert AA, Clinical Therapeutics, 28(12), 1972, 2006
- Wolfram HW, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Bu Rger A, J. Allergy Clin. Immunol., 115(6), 1276, 2005
- Raison-Peyron N, Revue Franccaise D’allergologie et D'immunologie Clinique, 47, 55, 2007
- Michaels AS, Chandrasekaran SK, Shaw JE, Am. Inst. Chem. Eng. J., 21, 985, 1975
- Potts RO, Francoeur M, J. Invest. Dermatol., 96(4), 495, 1991
- Rauma M, Isaksson TS, Johanson G, Toxicol. Vitro, 20, 1183, 2006
- Mo JH, Kim MS, Khang G, Lee TA, Lee HK, Rhee J, Lee HB, Tissue Eng. Regen. Med., 4(2), 174, 2007
- Nolan LM, Corish J, Corrigan OI, Fitzpatrick D, Int. J. Pharm., 341(1-2), 114, 2007
- Raders P, Aubry M, Friberg M, Huygens C, Koch T, Br. J. Nurs., 16(5), 312, 2007
- Lin SY, Curr Drug Deliv., 1(3), 249, 2004
- Lee CR, Kim MS, Lee HB, Lee HK, Rhee JM, Khang G, Key Eng. Mater., 342-343, 945, 2007
- Jang WY, Lee CR, Seo SM, Lee B, Kim MS, Khang G, Lee HG, Lee HB, J. Kor. Pharm. Sci., 35(6), 403, 2005
- Ito K, Kato Y, Tsuji H, Nguyen HT, Kubo Y, Tsuji A, J. Control. Release, 124, 60, 2007
- Schwindling SL, Michael F, Montenarh M, Eur. J. Cell Biol., 81, 169, 2002
- Kim SH, Yun SJ, Jang JW, Kim MS, Khang G, Lee HB, Polym.(Korea), 30(1), 14, 2006
- Wang PM, Cornwell M, Hill J, Prausniz MK, J. Invest. Dermatol., 126, 1080, 2006
- Martanto W, Moore JS, Couse T, Prausnitz MR, J. Control. Release, 112, 357, 2006
참고문헌정보(참고문헌, 인용문헌)는 화학공학소재연구정보센터에 의해 제공되고 있습니다.